Table 4 Effect estimates and quality of evidence ratings for comparisons in pairwise meta-analyses on secondary outcomes at 4-week follow-up
Outcome | Study design (Number of participants) | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Pooled result (95% CI) | Quality |
|---|---|---|---|---|---|---|---|---|
Alleviation of postprandial fullness | 8 RCTs (609 participants) | No serious | Serious | No serious | No serious | Not applicable | SMD: − 1.08 (− 1.64, − 0.51) | ⨁⨁⨁◯ Moderate |
Alleviation of postprandial fullness (Included only RCTs on CHM versus domperidone) | 6 RCTs (489 participants) | No serious | Serious | No serious | Serious | Not applicable | SMD: − 0.81 (− 1.37, − 0.24) | ⨁⨁◯◯ Low |
Alleviation of postprandial fullness (Included only RCTs on CHM versus mosapride) | 2 RCTs (120 participants) | No serious | Serious | No serious | Very serious | Not applicable | SMD: − 1.97 (− 3.79, − 0.16) | ⨁◯◯◯ Very low |
Alleviation of early satiety | 4 RCTs (326 participants) | No serious | Serious | No serious | Very serious | Not applicable | SMD: − 1.19 (− 2.40, 0.10) | ⨁◯◯◯ Very low |
Alleviation of epigastric burning | 2 RCTs (154 participants) | No serious | Serious | No serious | Very serious | Not applicable | SMD: − 1.93 (− 4.29, 0.43) | ⨁◯◯◯ Very low |
Alleviation of epigastric pain | 4 RCTs (326 participants) | No serious | No serious | No serious | Very serious | Not applicable | SMD: − 0.84 (− 1.10, − 0.58) | ⨁⨁◯◯ Low |